journal article·2022-05

Thiol-reacting toluidine blue derivatives: Synthesis, photophysical properties and covalent conjugation with human serum albumin

Nory Mariño-Ocampo, Juan S. Reyes, Germán Günther, Belinda Heyne, Denis Fuentealba

Dyes and Pigments· Volume 201
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics · Porphyrin and Phthalocyanine Chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (59)

Show source-provided references
1. Hamblin · 2008
2. Application of 5-aminolevulinic acid-photodynamic therapy in common skin diseases
3. Photodynamic inactivation of porphyromonas gingivalis utilizing radachlorin and toluidine blue O as photosensitizers: an in vitro study10.15171/jlms.2018.21 ↗
4. Near-infrared-triggered antibacterial and antifungal photodynamic therapy based on lanthanide-doped upconversion nanoparticles10.1039/C8NR01967C ↗
5. Blue photosensitizers for aPDT eliminate Aggregatibacter actinomycetemcomitans in the absence of light: an in vitro study10.1016/j.jphotobiol.2019.03.005 ↗
6. Photosensitization reactions of biomolecules: definition, targets and mechanisms10.1111/php.13470 ↗
7. Type I and type II photosensitized oxidation reactions: guidelines and mechanistic pathways10.1111/php.12716 ↗
8. The oxidative environment and protein damage10.1016/j.bbapap.2004.08.007 ↗
9. Singlet oxygen-mediated damage to proteins and its consequences10.1016/S0006-291X(03)00817-9 ↗
10. Photodynamic therapy of cancer: an update
11. Photodynamic therapy (PDT) of cancer: from local to systemic treatment10.1039/c5pp00132c ↗
12. Oncologic photodynamic therapy photosensitizers: a clinical review10.1016/j.pdpdt.2010.02.001 ↗
13. Photodynamic therapy (PDT): PDT mechanisms10.5946/ce.2013.46.1.24 ↗
14. Cucurbit[8]uril regulated activatable supramolecular photosensitizer for targeted cancer imaging and photodynamic therapy10.1021/acsami.6b07507 ↗
15. Supramolecular reversible on-off switch for singlet oxygen using cucurbit[n]uril inclusion complexes10.1021/acs.jpcc.7b07736 ↗
16. Mechanism of visible-light photooxidative demethylation of toluidine blue O10.1021/acs.jpca.9b03588 ↗
17. Biosupramolecular complexes of amphiphilic photosensitizers with human serum albumin and cucurbit[7]uril as carriers for photodynamic therapy10.1016/j.jphotobiol.2021.112284 ↗
18. Fatty acid conjugates of toluidine blue O as amphiphilic photosensitizers: synthesis, solubility, photophysics and photochemical properties10.1111/php.13304 ↗
19. Effects of toluidine blue O (TBO)-photodynamic inactivation on community-associated methicillin-resistant Staphylococcus aureus isolates10.1016/j.jmii.2014.12.007 ↗
20. Role of toluidine blue-O binding mechanism for photooxidation in bioinspired bacterial membranes10.1021/acs.langmuir.9b03045 ↗
21. Toluidine blue staining of the esophagus: a useful adjunct in the panendoscopic evaluation of patients with squamous cell carcinoma of the head and neck10.1001/archotol.1987.01860080070019 ↗
22. Toluidine blue: a review of its chemistry and clinical utility10.4103/0973-029X.99081 ↗
23. pH dependence of singlet oxygen production in aqueous solutions using thiazine dyes as photosensitizers10.1111/j.1751-1097.1975.tb06646.x ↗
24. Binding interactions of toluidine blue O with Escherichia coli DNA: formation of bridged structure10.1007/s10895-010-0829-4 ↗
25. Photodynamic therapy with toluidine blue in Jurkat cells: cytotoxicity, subcellular localization and apoptosis induction10.1039/b204385h ↗
26. Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands10.1016/S0031-6997(24)01447-9 ↗
27. Targeted photodynamic therapy via receptor mediated delivery systems10.1016/j.addr.2003.08.015 ↗
28. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy10.1039/C5CS00158G ↗
29. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles10.1016/j.jconrel.2008.05.010 ↗
30. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound10.1016/j.jconrel.2019.01.010 ↗
31. Peters · 1996
32. A clinical update of using albumin as a drug vehicle — a commentary10.1016/j.jconrel.2014.03.013 ↗
33. Modulation of the reactivity of the thiol of human serum albumin and its sulfenic derivative by fatty acids10.1016/j.abb.2012.03.011 ↗
34. Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding10.1088/1361-6528/aa6a9b ↗
35. Impact of albumin on drug delivery — new applications on the horizon10.1016/j.jconrel.2011.09.069 ↗
36. Homocysteine and cysteine – albumin binding in homocystinuria: assessment of cysteine status and implications for glutathione synthesis?10.1007/s007260200000 ↗
37. A unique mechanism for thiolation of serum albumins by disulphide molecules
38. Native albumin for targeted drug delivery10.1517/17425247.2010.498474 ↗
39. Self-assembled biodegradable protein–polymer vesicle as a tumor-targeted nanocarrier10.1021/am404734c ↗
40. Direct determination of thiol pKa by isothermal titration microcalorimetry10.1021/ja047929u ↗
41. The thiol of human serum albumin: acidity, microenvironment and mechanistic insights on its oxidation to sulfenic acid10.1016/j.freeradbiomed.2017.04.021 ↗
42. Quick measurement of protein sulfhydryls with Ellman's reagent and with 4,4'-dithiodipyridine10.1007/s00216-002-1347-2 ↗
43. Explaining the highly enantiomeric photocyclodimerization of 2-anthracenecarboxylate bound to human serum albumin using time-resolved anisotropy studies10.1021/ja3081555 ↗
44. Guest binding dynamics with cucurbit[7]uril in the presence of cations10.1021/ja209266x ↗
45. Nonell · 2000 · 37
46. Roles of near and far fields in plasmon-enhanced singlet oxygen production10.1021/acs.jpclett.9b01165 ↗
47. Singlet oxygen partition between the outer-, inner- and membrane-phases of photo/chemotherapeutic liposomes10.1039/C9CP05159G ↗
48. Quantum yields for the photosensitized formation of the lowest electronically excited singlet state of molecular oxygen in solution10.1063/1.555934 ↗
49. Characterization of disulfide bond position in proteins and sequence analysis of cystine-bridged peptides by tandem mass spectrometry10.1016/0003-2697(92)90331-Z ↗
50. Mechanisms and energetics of free radical initiated disulfide bond cleavage in model peptides and insulin by mass spectrometry10.1039/C5SC01305D ↗
51. Mass spectral studies. III. Fragmentation of aromatic amides10.1021/ja01072a023 ↗
52. Sulfur chemistry in polymer and materials science10.1002/marc.201800650 ↗
53. Reactivity of the thiol group in human and bovine albumin at pH 3–9, as measured by exchange with 2,2′-dithiodipyridine10.1111/j.1432-1033.1980.tb06022.x ↗
54. Potential applications of cucurbit[n]urils inclusion complexes in photodynamic therapy10.1002/ijch.201700093 ↗
55. Chemistry of singlet oxygen. 42. Effect of solvent, solvent isotopic substitution, and temperature on the lifetime of singlet molecular oxygen (1.DELTA. g)10.1021/ja00349a007 ↗
56. Physical mechanisms of generation and deactivation of singlet oxygen10.1021/cr010371d ↗
57. Detection of oxygen species and singlet oxygen
58. Photoactive assemblies of organic compounds and biomolecules: drug-protein supramolecular systems10.1039/C3CS60413F ↗
59. Sulfenic acid in human serum albumin10.1007/s00726-006-0430-y ↗